The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.
Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).
Guru Sonpavde, MD, medical director of genitourinary oncology at the AdventHealth Cancer Institute, discussed the promising findings of the CheckMate 901 trial exploring the potential of nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.
Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.